Case Report: A Successful Second Autologous Hematopoietic Stem Cell Transplantation in Refractory Systemic Sclerosis, with Positive Effect on Skin Involvement, Pulmonary Function and Microcirculation

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Dec 12

PMID 36505455

Authors

D A Haverkort

B E Kersten

A van Rhenen

W J F M van der Velden

M C Vonk

Affiliations

Soon will be listed here.

Abstract

Background: Systemic sclerosis (SSc) is a complex autoimmune disease characterized by inflammation, vasculopathy and fibrosis of the skin and internal organs. Treatment with autologous hematopoietic cell transplantation (HCT) for progressive SSc has improved overall and event-free survival rates significantly, but unfortunately disease progression after HCT is seen in a subset of patients. Data on the efficacy and safety of second HCT is scarce.

Case: We present a patient with diffuse cutaneous SSc and associated interstitial lung disease (ILD) who successfully underwent a second HCT for progressive disease five years after a first HCT. We describe changes in skin involvement and pulmonary involvement as well as the changes observed in sequential nailfold microcapillaroscopy (NCM), performed from first presentation up to this moment.

Conclusion: This case adds to the current limited literature on efficacy and safety of a second HCT in SSc refractory cases. Furthermore it outlines the potential of HCT on amelioration of microvasculopathy in SSc.

Citing Articles

Microvascular remodeling after autologous stem cell transplant in an overlap of systemic sclerosis and systemic lupus erythematosus: A case report.

Mumtaz S, Balistreri L, Abril A, Ayala E, Butendieck Jr R, Berianu F SAGE Open Med Case Rep. 2024; 12:2050313X241271811.

PMID: 39185071 PMC: 11342424. DOI: 10.1177/2050313X241271811.

Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience.

Boutel M, Boutou A, Pitsiou G, Garyfallos A, Dimitroulas T Diagnostics (Basel). 2023; 13(7).

PMID: 37046439 PMC: 10093288. DOI: 10.3390/diagnostics13071221.

References

Gressenberger P, Jud P, Kovacs G, Kreuzer S, Brezinsek H, Guetl K . Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis. J Pers Med. 2021; 11(7). PMC: 8305780. DOI: 10.3390/jpm11070600. View

Goswami R, Ray A, Chatterjee M, Mukherjee A, Sircar G, Ghosh P . Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Rheumatology (Oxford). 2020; 60(2):557-567. DOI: 10.1093/rheumatology/keaa550. View

Haentzschel I, Freiberg-Richter J, Platzbecker U, Kiani A, Schetelig J, Illmer T . Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bone Marrow Transplant. 2008; 42(2):113-20. DOI: 10.1038/bmt.2008.85. View

van Laar J, Farge D, Sont J, Naraghi K, Marjanovic Z, Larghero J . Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014; 311(24):2490-8. DOI: 10.1001/jama.2014.6368. View

Sulli A, Paolino S, Pizzorni C, Ferrari G, Pacini G, Pesce G . Progression of nailfold capillaroscopic patterns and correlation with organ involvement in systemic sclerosis: a 12 year study. Rheumatology (Oxford). 2019; 59(5):1051-1058. DOI: 10.1093/rheumatology/kez374. View

Smith V, Herrick A, Ingegnoli F, Damjanov N, De Angelis R, Denton C . Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. Autoimmun Rev. 2020; 19(3):102458. DOI: 10.1016/j.autrev.2020.102458. View

Ciaffi J, van Leeuwen N, Huizinga T, de Vries-Bouwstra J . Smoking and systemic sclerosis: influence on microangiopathy and expression of anti-topoisomerase I antibodies in a monocentric cohort. Clin Exp Rheumatol. 2020; 38 Suppl 125(3):25-28. View

Goh N, Desai S, Veeraraghavan S, Hansell D, Copley S, Maher T . Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008; 177(11):1248-54. DOI: 10.1164/rccm.200706-877OC. View

Burt R, Shah S, Dill K, Grant T, Gheorghiade M, Schroeder J . Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011; 378(9790):498-506. DOI: 10.1016/S0140-6736(11)60982-3. View

10.

Lemieux C, Muffly L, Iberri D, Craig J, Johnston L, Lowsky R . Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplant. 2021; 56(11):2664-2671. PMC: 8715953. DOI: 10.1038/s41409-021-01371-1. View

11.

Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B . American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic.... Biol Blood Marrow Transplant. 2015; 21(12):2039-2051. PMC: 4757494. DOI: 10.1016/j.bbmt.2015.09.016. View

12.

van Rhijn-Brouwer F, Spierings J, van Rhenen A, Kuball J, van Laar J . Second autologous haematopoietic stem cell transplantation in systemic sclerosis-a case report. Rheumatology (Oxford). 2019; 58(7):1305-1307. PMC: 6587916. DOI: 10.1093/rheumatology/kez010. View

13.

Khanna D, Lin C, Furst D, Goldin J, Kim G, Kuwana M . Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020; 8(10):963-974. DOI: 10.1016/S2213-2600(20)30318-0. View

14.

Sullivan K, Goldmuntz E, Keyes-Elstein L, McSweeney P, Pinckney A, Welch B . Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018; 378(1):35-47. PMC: 5846574. DOI: 10.1056/nejmoa1703327. View

15.

Duarte R, Labopin M, Bader P, Basak G, Bonini C, Chabannon C . Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019; 54(10):1525-1552. DOI: 10.1038/s41409-019-0516-2. View

16.

Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y . Defective vasculogenesis in systemic sclerosis. Lancet. 2004; 364(9434):603-10. DOI: 10.1016/S0140-6736(04)16853-0. View

17.

Cutolo M, Sulli A, Pizzorni C, Accardo S . Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol. 2000; 27(1):155-60. View

18.

Miniati I, Guiducci S, Conforti M, Rogai V, Fiori G, Cinelli M . Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann Rheum Dis. 2008; 68(1):94-8. DOI: 10.1136/ard.2007.082495. View

19.

Lemmers J, Velauthapillai A, van Herwaarden N, Vonk M . Change of the microvascularization in systemic sclerosis, a matter of air. Best Pract Res Clin Rheumatol. 2021; 35(3):101683. DOI: 10.1016/j.berh.2021.101683. View

20.

van Bijnen S, de Vries-Bouwstra J, van den Ende C, Boonstra M, Kroft L, Geurts B . Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. Ann Rheum Dis. 2020; 79(8):1084-1089. DOI: 10.1136/annrheumdis-2020-217058. View